Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI112 (Picankibart) in Moderate to Severe Plaque Psoriasis
NCT06049810Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of picankibart in plaque psoriasis (6 arms), sponsored by Innovent Biologics. Primary endpoint: Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response at Week 56. Started Oct 2023; status: completed.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06049810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049810.